Literature DB >> 8557994

A20 zinc finger protein inhibits TNF and IL-1 signaling.

M Jäättelä1, H Mouritzen, F Elling, L Bastholm.   

Abstract

A20 zinc finger protein is a product of a cytokine-induced primary response gene. In this report, we demonstrate that A20 specifically inhibits signal transduction pathways induced by TNF and IL-1, suggesting that it functions as a negative regulator of the cytokine response. Overexpression of A20 in MCF7 breast carcinoma cells or in WEHI-S fibrosarcoma cells inhibits apoptosis induced by TNF, whereas cytotoxicity induced by anti-Fas (anti-CD95); lymphokine-activated killer (LAK) cells, serum starvation, oxidative stress, or okadaic acid is not inhibited. Overexpression of A20 also inhibits TNF-induced activation of phospholipase A2 in a similar dose-dependent manner as it inhibits TNF-mediated apoptosis, whereas it does not affect the activation of phospholipase A2 by anti-Fas. Interestingly, A20 also blocks TNF-induced signal transduction pathways not directly related to the cytotoxicity, namely activation of NF-kappa B and AP-1 transcription factors. Activation of these transcription factors by a functionally related cytokine, IL-1, is also inhibited by A20, whereas activation induced by hydrogen peroxide or phorbol ester is unaffected. Overexpression of A20 does not affect the binding of TNF to its cell surface receptors. These data suggest that A20 functions as a negative regulator of TNF and IL-1, interfering with signal transduction pathways at an early point following receptor binding but before the activation of various second messengers, leading to the wide variety of effects induced by these cytokines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8557994

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  77 in total

Review 1.  Death receptor signaling and autoimmunity.

Authors:  Richard M Siegel; Jagan Muppidi; Margaret Roberts; Melissa Porter; Zhengqi Wu
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  A20 suppresses vascular inflammation by recruiting proinflammatory signaling molecules to intracellular aggresomes.

Authors:  Karine Enesa; Herwig P Moll; Le Luong; Christiane Ferran; Paul C Evans
Journal:  FASEB J       Date:  2015-02-09       Impact factor: 5.191

3.  The ability of BHRF1 to inhibit apoptosis is dependent on stimulus and cell type.

Authors:  L Foghsgaard; M Jäättelä
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa.

Authors:  K Johnson; S Hashimoto; M Lotz; K Pritzker; R Terkeltaub
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 5.  ACOD1 in immunometabolism and disease.

Authors:  Runliu Wu; Feng Chen; Nian Wang; Daolin Tang; Rui Kang
Journal:  Cell Mol Immunol       Date:  2020-06-29       Impact factor: 11.530

Review 6.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

Review 7.  Host nucleotide polymorphism in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Shilu Mathew; Hany Abdel-Hafiz; Abbas Raza; Kaneez Fatima; Ishtiaq Qadri
Journal:  World J Hepatol       Date:  2016-04-08

8.  A20 inhibits tumor necrosis factor (TNF) alpha-induced apoptosis by disrupting recruitment of TRADD and RIP to the TNF receptor 1 complex in Jurkat T cells.

Authors:  Kai-Li He; Adrian T Ting
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

9.  The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation.

Authors:  Lianyun Li; Nia Soetandyo; Qiuyan Wang; Yihong Ye
Journal:  Biochim Biophys Acta       Date:  2008-10-08

Review 10.  Zinc in human health: effect of zinc on immune cells.

Authors:  Ananda S Prasad
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.